Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTRAS: MSK-TCR5 in Advanced Solid Tumors
NCT07638371Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2026
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
Phase 1, open-label trial of MSK-TCR5 in solid tumor (4 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of related toxicities at 1 year. Started Jun 2026; status: recruiting.
02
Drugs
MSK-TCR5
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07638371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07638371.